Diplomat Pharmacy Inc (DPLO) to Post FY2019 Earnings of $0.33 Per Share, William Blair Forecasts

Diplomat Pharmacy Inc (NYSE:DPLO) – Stock analysts at William Blair cut their FY2019 earnings estimates for Diplomat Pharmacy in a research note issued to investors on Monday, March 18th. William Blair analyst J. Kreger now forecasts that the company will post earnings of $0.33 per share for the year, down from their prior forecast of $0.50. William Blair currently has a “Underperform” rating on the stock. William Blair also issued estimates for Diplomat Pharmacy’s FY2020 earnings at $0.34 EPS.

DPLO has been the subject of a number of other research reports. ValuEngine cut Diplomat Pharmacy from a “sell” rating to a “strong sell” rating in a report on Monday, February 4th. TheStreet cut Diplomat Pharmacy from a “c-” rating to a “d+” rating in a report on Monday, March 4th. Zacks Investment Research cut Diplomat Pharmacy from a “hold” rating to a “sell” rating in a report on Wednesday, March 13th. Robert W. Baird raised Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and upped their price target for the stock from $10.00 to $15.00 in a report on Friday, December 7th. Finally, Svb Leerink cut Diplomat Pharmacy from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $24.00 to $6.00 in a report on Monday, February 25th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company. Diplomat Pharmacy currently has an average rating of “Hold” and a consensus target price of $11.10.

Shares of DPLO opened at $6.36 on Wednesday. Diplomat Pharmacy has a 52 week low of $5.16 and a 52 week high of $28.74. The company has a current ratio of 1.00, a quick ratio of 0.66 and a debt-to-equity ratio of 0.94. The stock has a market capitalization of $426.08 million, a PE ratio of 31.80 and a beta of 0.74.

Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Friday, March 15th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.10). Diplomat Pharmacy had a positive return on equity of 5.51% and a negative net margin of 5.50%. The company had revenue of $1.36 billion during the quarter, compared to analysts’ expectations of $1.41 billion. During the same quarter in the previous year, the company earned $0.09 EPS. The firm’s quarterly revenue was up 17.8% compared to the same quarter last year.

Several institutional investors have recently made changes to their positions in the business. BlackRock Inc. raised its holdings in shares of Diplomat Pharmacy by 2.2% during the fourth quarter. BlackRock Inc. now owns 8,650,451 shares of the company’s stock valued at $116,435,000 after acquiring an additional 186,200 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Diplomat Pharmacy by 9.4% during the third quarter. Janus Henderson Group PLC now owns 5,892,046 shares of the company’s stock valued at $114,365,000 after acquiring an additional 506,878 shares during the last quarter. Vanguard Group Inc raised its holdings in shares of Diplomat Pharmacy by 4.0% during the third quarter. Vanguard Group Inc now owns 5,461,715 shares of the company’s stock valued at $106,011,000 after acquiring an additional 209,939 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Diplomat Pharmacy by 4.0% during the third quarter. Vanguard Group Inc. now owns 5,461,715 shares of the company’s stock valued at $106,011,000 after acquiring an additional 209,939 shares during the last quarter. Finally, Capital International Investors acquired a new position in shares of Diplomat Pharmacy during the third quarter valued at approximately $99,092,000. 86.57% of the stock is owned by institutional investors and hedge funds.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Featured Article: How are dividend achievers different from dividend aristocrats?

Earnings History and Estimates for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.